EXCLUSIVE: TransCode's RNA Therapeutic TTX-MC138 Achieves 64% Stable Disease Rate Lasting Six Months In Phase 1a Trial; Reports Positive Safety And Disease Stabilization Data

Benzinga Newsdesk www.benzinga.com Positive 94.8%

Neg 0% Neu 0% Pos 94.8%

Comments

No comments yet. Be the first!